4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD

23 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

4DMT Appoints Uneek Mehra as Chief Financial and Business Officer

12 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

07 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire

4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD

07 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights

09 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023

29 июл 2023 12:00:00 Источник Nasdaq GlobeNewswire

4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data

17 июл 2023 16:05:00 Источник Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting

07 июн 2023 16:10:17 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

01 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting

24 май 2023 08:00:01 Источник Nasdaq GlobeNewswire

4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

11 май 2023 08:00:01 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

10 май 2023 16:05:01 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

09 май 2023 16:05:01 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

08 май 2023 16:05:01 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

04 май 2023 21:04:59 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

04 май 2023 16:08:59 Источник Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023

27 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire

4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy

24 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire

4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer

13 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights

15 мар 2023 16:05:01 Источник Nasdaq GlobeNewswire